Work

Cardiomyopathy due to Pegylated Interferon Therapy for Hepatitis C

Year: 2014

Type: article

Abstract: Pegylated interferon is an important drug in the treatment of Hepatitis C. Cardiomyopathy due to interferon is rare but can be fatal. With increasing incidence of hepatitis C, more patients are being treated with Interferon based therapy. We report a case of 53 year old man who presented with new onset congestive heart failure within 11 weeks of starting triple therapy with pegylated interferon for Hepatitis C infection. Patient had a remote history of cocaine, alcohol, tobacco use, family history of coronary artery disease, congestive heart failure but he never had a previous cardiac work up. We suggest getting a baseline Echocardiogram in patients who are at high risk for cardiomyopathy before starting interferon therapy.

Source: International Journal of Internal Medicine

Authors: Punita Kaveti, Erica T. Isom, Kelly Schrapp, Marvin Crawford

Language: English

Topic: Hepatitis C virus research

Subfield: Hepatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

OpenAlex ID: W81182470

FWCI:

Cites: 8

Cited by:

Related to: 10